Biotech

All Articles

AN 2 fifty percents head count, ceases phase 3 test after data let down

.AN2 Therapeutics is actually rethinking its company in action to lackluster midphase information, s...

Merck pays out $700M for bispecific, snooping autoimmune position and also opportunity to challenge Amgen in cancer cells

.Merck &amp Co. is actually paying for $700 million beforehand to challenge Amgen in a blood cancer ...

Gilead spends J&ampJ $320M to exit licensing bargain for seladelpar

.With Gilead Sciences almost an FDA decision for its own liver disease drug seladelpar, the provider...

' All hands on deck' at Lilly as peers target obesity market

.CEO David Ricks can see the firms putting together camping tents at basecamp responsible for Eli Li...

Entero laying off personnel, vacating workplace as well as stopping R&ampD

.Mattress Liquidators has actually turned Entero Therapeutics white as a sheet. The creditor purchas...

Exelixis loses ADC after choosing it is actually no suit for Tivdak

.Exelixis is actually losing hope on its cells variable (TF)- targeting antibody-drug conjugate afte...

Relay loses interest in SHP2 prevention after Genentech leaves

.3 full weeks after Roche's Genentech device bowed out an SHP2 prevention pact, Relay Therapeutics h...

Stoke's Dravet syndrome med released of predisposed professional hold

.Stoke Therapies' Dravet disorder medication has actually been actually devoid of a partial hold, re...

Fierce Biotech's Gabrielle Masson shows Fierce 15 at NYSE

.Ferocious Biotech Associate Editor Gabrielle Masson presented the 2024 class of Strong 15 victors o...

Novo Nordisk centers once-monthly GLP-1\/ GIP agonist, MASH possibility

.Novo Nordisk has axed its own once-monthly twin GLP-1/ GIP receptor agonist, finishing (PDF) progre...